Abbott Laboratories (BCBA:ABT)
Argentina
· Delayed Price · Currency is ARS 47,420
+420 (0.89%)
At close: Dec 5, 2025
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| United States Revenue | 17.08B | 16.32B |
Log In |
Log In |
Log In | Upgrade
|
| Germany Revenue | - | 2.54B |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue | - | 2.11B |
Log In |
Log In |
Log In | Upgrade
|
| India Revenue | - | 1.82B |
Log In |
Log In |
Log In | Upgrade
|
| Switzerland Revenue | - | 1.75B |
Log In |
Log In |
Log In | Upgrade
|
| Japan Revenue | - | 1.44B |
Log In |
Log In |
Log In | Upgrade
|
| Netherlands Revenue | - | 1.12B |
Log In |
Log In |
Log In | Upgrade
|
| All Other Countries Revenue | - | 14.85B |
Log In |
Log In |
Log In | Upgrade
|
| Total International Revenue | 26.76B | 25.63B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 43.84B | 41.95B |
Log In |
Log In |
Log In | Upgrade
|
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Established Pharmaceutical Products Revenue | 5.42B | 5.19B |
Log In |
Log In |
Log In | Upgrade
|
| Nutritionals Revenue | 8.64B | 8.41B |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Revenue | 9.00B | 9.34B |
Log In |
Log In |
Log In | Upgrade
|
| Medical Devices Revenue | 20.76B | 18.99B |
Log In |
Log In |
Log In | Upgrade
|
| Other Segment Revenue | 17.00M | 16.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 43.84B | 41.95B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Established Pharmaceutical Products Operating Earnings | 1.31B | 1.23B |
Log In |
Log In |
Log In | Upgrade
|
| Nutritionals Operating Earnings | 1.62B | 1.51B |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Operating Earnings | 1.74B | 2.07B |
Log In |
Log In |
Log In | Upgrade
|
| Medical Devices Operating Earnings | 7.01B | 6.15B |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | -3.96B | -4.14B |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 7.71B | 6.83B |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2019 |
| Organic Sales Growth | 9.60% |
Log In |
Log In |
Log In | Upgrade
|